[Pregabalin: new therapeutic contributions of calcium channel alpha2delta protein ligands on epilepsy and neuropathic pain].
OBJECTIVE
To review and update the contributions of a new class of drugs, named calcium channel alpha2delta protein ligands, on the treatment of epilepsy and neuropathic pain.


METHODS
A novel class of anticonvulsants are ligands for the auxiliary-associated protein alpha2delta subunit of voltage-gated calcium channels in the central nervous system. Gabapentin and pregabalin are members of this group. Pregabalin is a higher-potency and higher-effective analogue of gabapentin that act as a potent ligand for this site. The anticonvulsant action of pregabalin is probably due to its ability to reduce neurotransmitter release from activated epileptogenic neurons, without demonstrated effects on GABAergic receptors or mechanisms. In well-done clinical trials, pregabalin 150-600 mg/day has been shown to be highly effective and well tolerated as adjunctive therapy in patients with partial seizures. In several randomized, double-blind, clinical trials, oral pregabalin 150-600 mg/day was superior to placebo in relieving neuropathic pain associated with diabetic neuropathy and postherpetic neuralgia. Pregabalin demonstrates in humans an extensive and rapid absorption and a highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. The pharmacological activity of pregabalin is similar but not identical to that of gabapentin, and pregabalin shows possible advantages.


CONCLUSIONS
Pregabalin and calcium channel alpha2delta protein ligands showed relevant advances on epilepsy and neuropathic pain treatment. In peripheral neuropathic pain conditions, if the criteria for efficacy are based on both pain relief and quality of life measures, pregabalin/gabapentin are suggested as choice treatment.
Horga de la Parte
J F
JF
Unidad de Farmacología Clínica, Hospital General Universitario de Alicante, Alicante, Spain. horga_jos@gva.es
Horga
A
A
D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D015220:Calcium Channels / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008024:Ligands; D009437:Neuralgia / Q000188:drug therapy*; D010919:Placebos; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000700:Analgesics; D000927:Anticonvulsants; C425903:CACNA2D1 protein, human; D015220:Calcium Channels; D008024:Ligands; D010919:Placebos; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid